Cellebrite DI (NASDAQ:CLBT) Stock Gets Price Target Bump from Needham & Company LLC

Cellebrite DI (NASDAQ:CLBT) had its target price lifted by investment analysts at Needham & Company LLC from $12.50 to $14.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC‘s target price would indicate a potential upside of 28.56% from the stock’s previous close.

A number of other research analysts have also weighed in on CLBT. Lake Street Capital cut their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. DA Davidson reiterated a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings lowered Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. Finally, JPMorgan Chase & Co. cut their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Cellebrite DI Stock Performance

CLBT opened at $10.89 on Thursday. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 1.95 and a beta of 1.06. The company has a fifty day moving average of $11.61 and a 200 day moving average of $13.24. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.98.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, November 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.09 by $0.08. The business had revenue of $149.02 million for the quarter, compared to analysts’ expectations of $145.83 million. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. On average, equities research analysts forecast that Cellebrite DI will post 0.37 earnings per share for the current year.

Insider Buying and Selling at Cellebrite DI

In other news, CMO David Gee sold 4,323 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $11.36, for a total value of $49,109.28. Following the sale, the chief marketing officer directly owned 135,281 shares in the company, valued at $1,536,792.16. The trade was a 3.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas E. Hogan sold 25,299 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the sale, the insider owned 765,249 shares in the company, valued at $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 56,909 shares of company stock valued at $641,890. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently added to or reduced their stakes in the stock. Nine Ten Capital Management LLC lifted its stake in shares of Cellebrite DI by 19.8% in the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after purchasing an additional 682,933 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Cellebrite DI by 93.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after purchasing an additional 1,475,579 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after purchasing an additional 365,700 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Cellebrite DI by 33.9% during the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after buying an additional 545,334 shares during the period. Finally, Weiss Asset Management LP raised its holdings in Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after buying an additional 1,846,851 shares during the period. 45.88% of the stock is owned by institutional investors.

Trending Headlines about Cellebrite DI

Here are a few of the latest headlines about CLBT:

• Positive Sentiment: Q3 revenue was $149.0 million, above the $145.8 million analyst estimate, while EPS was $0.17. The company also reported 20% ARR growth, $26.7 million in net income, and a 31% trailing-twelve-month free-cash-flow margin. Cellebrite Reports Third-Quarter 2026 Results
• Neutral Sentiment: Chief Revenue Officer Marcus Jewell sold 393 shares, a 0.09% reduction in his holdings; he retained 426,735 shares, making the sale relatively small. SEC filing
• Negative Sentiment: Q4 revenue guidance of $145 million to $150 million fell short of the $151.6 million analyst consensus. This cautious near-term outlook may be outweighing the Q3 beat and growth metrics.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.